 |
|
Cyclophosphamide in Chronic Progressive Multiple SclerosisMaintenance vs Nonmaintenance Therapy
Donald E. Goodkin, MD;
Stacy Plencner, RPT;
Jeanine Palmer-Saxerud, OTR;
Merle Teetzen, MD;
Doris Hertsgaard, PhD
Arch Neurol. 1987;44(8):823-827.
Abstract
• Twenty-seven patients with chronic progressive multiple sclerosis were treated with high-dose intravenous cyclophosphamide induction on either an inpatient or outpatient basis. Following induction, patients were randomized to alternate-month outpatient "maintenance" or "no maintenance" therapy. These groups, as well as 24 nonrandomized control patients, were compared with each other after 12, 18, and 24 months of follow-up. All groups were similar in age, sex, duration of disease, and degree of disability before treatment. Fifty-nine percent of all cyclophosphamide-treated patients were stable at 12 months compared with 17% of all patients in the nonrandomized control group at 12 months. A statistically significant difference persisted at 18 and 24 months. A trend favoring maintenance therapy when compared with no maintenance therapy was evident at 12, 18, and 24 months, but was not statistically significant. Inpatient vs outpatient induction therapy failed to influence treatment outcome. Toxic side effects of nausea and vomiting presented a serious obstacle to maintenance therapy as administered in this protocol.
Author Affiliations
From the Division of Neurology, University of North Dakota, Grand Forks, and The Neuropsychiatric Institute, Fargo, ND (Drs Goodkin and Hertsgaard); Grand Forks (ND) Clinic (Dr Teetzen); and Dakota Medical Center, Fargo, ND (Mss Plencner and Palmer-Saxerud).
Footnotes
Accepted for publication Jan 9, 1987.
Reprint requests to The Neuropsychiatric Institute, 700 First Ave S, Fargo, ND 58103 (Dr Goodkin).
 CiteULike  Connotea  Delicious  Digg  Facebook  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Chemotherapeutics in the treatment of multiple sclerosis
Kieseier and Jeffery
Therapeutic Advances in Neurological Disorders 2010;3:277-291.
ABSTRACT
Safety and tolerability of cyclophosphamide 'pulses' in multiple sclerosis: a prospective study in a clinical cohort
Portaccio et al.
Mult Scler 2003;9:446-450.
ABSTRACT
Treatment of multiple sclerosis with cyclophosphamide: critical review of clinical and immunologic effects
Weiner and Cohen
Mult Scler 2002;8:142-154.
ABSTRACT
Combination of cyclophosphamide and interferon-{beta} halts progression in patients with rapidly transitional multiple sclerosis
Patti et al.
J. Neurol. Neurosurg. Psychiatry 2001;71:404-407.
ABSTRACT
| FULL TEXT
Treatment of progressive multiple sclerosis with pulse cyclophosphamidel methylprednisolone: Response to therapy is linked to the duration of progressive disease
Hohol et al.
Mult Scler 1999;5:403-409.
ABSTRACT
Population Dynamics of the Disability Status Scales for Multiple Sclerosis
Quick and Schapiro
Neurorehabil Neural Repair 1996;10:127-134.
ABSTRACT
Exacerbation Rates and Adherence to Disease Type in a Prospectively Followed-up Population With Multiple Sclerosis: Implications for Clinical Trials
Goodkin et al.
Arch Neurol 1989;46:1107-1112.
ABSTRACT
|
